Clinical trials: Cannabidiol
Anorexia Nervosa
Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa
No studies of cannabidiol (CBD) have focused on Anorexia Nervosa (AN). Dose, side effects, tolerability, acceptability of pure CBD in AN must be established.
- Trial name
- NCT04878627
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Diego
Lennox-Gastaut Syndrome
Investigation of Cognitive Outcomes With Cannabidiol Oral Solution
This study is being conducted to evaluate the effects of GWP42003-P on cognition in pediatric participants, aged 3 to 10 years, with Lennox-Gastaut Syndrome (LGS).
- Trial name
- EPI-COG (NCT04133480)
- Testing
- GWP42003-P
- Sponsor
- Jazz Pharmaceuticals
Pain
Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol)
This project is intended to evaluate self-emulsifying drug delivery system termed Piperine-Pro-Nano-Lipospheres (P-PNL) for enhancing the oral bioavailability of tetrahydrocannabinol (THC) and cannabidiol (CBD).The oral…
- Trial name
- NCT01893424
- Testing
- Sativex buccal spray, CBD-THC-Piperine-PNL capsule
- Where
- Israel
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Osteoarthritis, Knee, Osteoarthritis of the Knee
Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee
This clinical trial is being done to better understand how daily treatment with Tetrahydrocannabinol (THC), Cannabidiol (CBD), or the combination of CBD plus THC affects knee osteoarthritis pain and other related symptoms.
- Trial name
- NCT04992624
- Testing
- Cannabidiol (CBD), Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Steven E Harte, PhD
Epilepsy
Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy
Part A: To evaluate the safety and tolerability of multiple ascending doses of GWP42003-P compared with placebo with respect to: Incidence, type and severity of adverse events (AEs) Effect on vital signs, including weight Effect…
- Trial name
- NCT02286986
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Utah
Temporomandibular Disorder, Myofascial Pain
CBD (Cannabidiol) Intraoral Application and TMD (Temporomandibular Disorders)
The aim of the project is to assess the effectiveness of reducing the masseter muscles tension and hyperactivity in patients with a painful form of TMD by using polymers containing CBD compared to placebo polymers.
- Conditions
- Temporomandibular Disorder, Myofascial Pain, Orofacial Pain, CBD
- Trial name
- NCT05562635
- Testing
- 5% polymer gel with CBD application, 10% polymer gel with CBD application
- Where
- Poland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Medical University of Silesia
COVID-19
Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection
Current management of COVID-19 (coronavirus) is mainly supportive, and respiratory failure from acute respiratory distress syndrome (ARDS) is the leading cause of mortality.
- Trial name
- NCT04731116
- Testing
- Cannabidiol
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Rabin Medical Center
Alzheimer Disease, Anxiety
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
This is an open label, eight week, clinical trial of a proprietary high CBD/low THC sublingual solution for the treatment of clinically significant anxiety and agitation in individuals with mild cognitive impairment (MCI) or mild…
- Conditions
- Alzheimer Disease, Anxiety, Agitation,Psychomotor, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
- Trial name
- CBD (NCT04075435)
- Testing
- high CBD/low THC sublingual solution
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mclean Hospital
SCI - Spinal Cord Injury, Neuropathic Pain
Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI
The main purposes of this study are to (1) measure the effect of CBD/CBD-A on pain symptoms, pain intensity, pain unpleasantness, and skin sensitivity to hot and cold temperatures; and (2) measure the effect of CBD on brain…
- Trial name
- NCT05630235
- Testing
- CBD/CBD-A
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Infantile Spasms
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
This trial consists of 3 parts: a pilot safety phase, a pivotal randomized controlled phase, and an open-label extension phase. The open-label extension phase only will be described in this record.
- Trial name
- NCT02954887
- Testing
- GWP42003-P
- Where
- 7 sites in United States, Poland
- Volunteers
- 9 people
- Sponsor
- Jazz Pharmaceuticals
Acute Nociceptive Pain, Hyperalgesia
Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults
Prospective, randomized, placebo-controlled, double-blinded, crossover study to investigate the effect of cannabidiol (CBD) on remifentanil-induced hyperalgesia in healthy volunteers in a well-established acute pain model.
- Conditions
- Acute Nociceptive Pain, Hyperalgesia, Allodynia, Opioid-induced Hyperalgesia
- Trial name
- CANAB II (NCT04059978)
- Testing
- CBD, Remifentanil
- Where
- Switzerland
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Pain, Abuse, Drug
Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia
The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-liability effects of a sub-threshold dose of a commonly used analgesic.
- Trial name
- NCT03679949
- Testing
- Oxycodone, Cannabis (THC:CBD = ~ 1:0), Cannabis (THC:CBD = ~ 0:1)
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Opioid-use Disorder
Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder
This research aims to determine the effects and safety of cannabidiol (CBD) (ATL5 softgel capsules) as an adjunctive therapy for patients who have Opioid Use Disorder and are taking buprenorphine + naloxone or methadone.
- Trial name
- NCT03787628
- Testing
- Cannabidiol (CBD) 600 mg
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, Los Angeles
Opiate Addiction
Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans
Despite the current available therapies for opioid-dependent patients, most patients relapse. This research project focuses on the development of a novel compound, cannabidiol, to modulate opioid craving in humans based on animal…
- Trial name
- NCT01605539
- Testing
- Cannabidiol 400, Cannabidiol 800, Control
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hurd,Yasmin, Ph.D.
Back Pain, Low
Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain
In this research, the study team will use brain imaging to evaluate the presence of neuroinflammation in the brains and spinal cords of patients with low back pain, and whether CBD effects levels of neuroinflammation.
- Trial name
- CBD (NCT03891264)
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Psychosis, First Episode Psychosis
Stratification and Treatment in Early Psychosis Study - ENHANCE
The purpose of this study is: To investigate whether the response to antipsychotic treatment can be enhanced by adding cannabidiol (CBD) to the existing treatment, compared to placebo, in participants with a first episode of…
- Conditions
- Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
- Trial name
- STEP-ENHANCE (NCT06778564)
- Testing
- CBD 100 mg/mL Oral Solution
- Where
- 17 sites in Austria, Germany and 7 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Multiple Sclerosis
An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An open-label extension study in which patients with multiple sclerosis received GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] for four weeks in an open-label manner.
- Trial name
- NCT01610713
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 154 people
- Sponsor
- Jazz Pharmaceuticals
Knee Replacement Surgery, Osteoarthritis, Knee
Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty
The goal of this study is to better understand how daily treatment with cannabidiol (CBD) affects the need for opioid pain medication, as well as pain, inflammation and other related symptoms, after knee replacement surgery.
- Trial name
- CORK (NCT06234631)
- Testing
- Epidiolex oral solution
- Where
- 2 sites in United States
- Volunteers
- 380 people
- Sponsor
- Chad Brummett
Anxiety
Cannabidiol for Anxiety
This pilot trial seeks to investigate the effect of 25 mg full-spectrum CBD soft gel capsules (up to a total dosage of 100mg per day) on individuals with diagnosed anxiety.
- Trial name
- NCT04267679
- Testing
- Cannabidiol
- Sponsor
- CB2 Insights
Chronic Spontaneous Urticaria
Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients
Each patient will commence the study with a one month run-in period in which he/she will be administered individual patient Standard of Care :anti-histamines and steroids as needed plus placebo (olive oil).
- Trial name
- NCT04439955
- Testing
- CBD
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Stero Biotechs Ltd.